Case Report: Cryoglobulinemic vasculitis after COVID-19 vaccination [version 1; peer review: awaiting peer review]

Since its occurrence, the coronavirus disease 2019 (COVID-19) pandemic has been responsible for a substantial rate of morbidity and mortality. The quick development of an effective and safe vaccine was essential in order to control the ongoing pandemic. However, given the severity of the situation,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:F1000 research 2023, Vol.12, p.1476
Hauptverfasser: Kechaou, Ines, Tekaya, Asma, Hamdi, Mohamed Salah, Jebri, Meryem, Cherif, Eya, Ben Hassine, Lamia
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Since its occurrence, the coronavirus disease 2019 (COVID-19) pandemic has been responsible for a substantial rate of morbidity and mortality. The quick development of an effective and safe vaccine was essential in order to control the ongoing pandemic. However, given the severity of the situation, mass-scale vaccination had to be undertaken without much hindsight. Subsequently, side effects of the anti-COVID-19 vaccine, such as autoimmune diseases, have been reported. Cryoglobulinemic vasculitis (CryoVas) is a rare auto-immune disease, caused by the presence in the serum of abnormal immunoglobulins (cryoglobulins) able to precipitate at temperatures below 37°C. CryoVas can be either essential or, more frequently, secondary to other diseases such as infections, malignancies and auto-immune diseases. In some cases, CryoVas can be vaccine-induced. We describe an original case of a 57-year-old woman with no medical history who presented with purpura of the lower limbs that appeared 5 days after receiving her first COVID-19 vaccine. Skin biopsy and immunological work out were consistent with CryoVas.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.142144.1